CGRP antibodies & migraine – findings so far

10th March 2017

CGRP (Calcitonin Gene Related Peptide) is a neuropeptide which is released into the blood stream during a migraine attack and it has a central role in the underlying mechanisms of a migraine attack.

Recent results from clinical trials targeting CGRP are encouraging and the drugs are now entering phase 3 late stage clinical trials to further evaluate the benefits and safety of these new therapies.

In this video clip at the European Academy of Neurology Congress 2016, Prof. Peter Goadsby discusses the rationale for using CGRP antibodies in the treatment of migraine and the study findings so far.

CGRP antibodies & migraine – findings so far

10th March 2017

CGRP (Calcitonin Gene Related Peptide) is a neuropeptide which is released into the blood stream during a migraine attack and it has a central role in the underlying mechanisms of a migraine attack.

Recent results from clinical trials targeting CGRP are encouraging and the drugs are now entering phase 3 late stage clinical trials to further evaluate the benefits and safety of these new therapies.

In this video clip at the European Academy of Neurology Congress 2016, Prof. Peter Goadsby discusses the rationale for using CGRP antibodies in the treatment of migraine and the study findings so far.